A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

Researchers are looking for new treatments for HIV-1 (human immunodeficiency virus type 1) that are safe, well-tolerated, and can be taken less often. HIV-1 is the most common type of HIV, which is a virus that attacks cells of the immune system. Ulonivirine (MK-8507) is a study medicine designed to treat HIV-1 The goal of this study is to learn if ulonivirine does not increase the QT interval (a measure of heart rhythm on an electrocardiogram) above a certain amount. Researchers also want to learn what happens to the amount of ulonivirine in a healthy person's body over time.

Key facts

Study ID

NCT07305831

Run by

Merck Sharp & Dohme LLC

People needed

62

Starts

2026-01-22

Expected to finish

2026-04-09

Last updated by the study team

2026-04-21

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Is in good health before randomization
• Has body Mass Index (BMI) between 18 and 32 kg/m2, inclusive

You may not qualify if…

• Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• Has history of cancer (malignancy)
• Has positive test(s) for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV)

Where it is running

• ICON Early Phase Services (0001) — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.